Patent EP0351891A2 successfully refreshed from Google Patents.
Patent EP0349215A1 successfully refreshed from Google Patents.
EP0349215A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method and cell for detection
Assignee: Meda Pharmaceuticals Inc
•
Filing: 1989-06-23
•
Granted: —
•
Expires: 2009-06-23
Abstract
Abstract A test cell (5) for detecting a ligand in a liquid sample, which comprises an elongate casing (10) for housing a permeable material (12) and defining a liquid sample inlet (14), a reservoir volume (24), a test volume (22) interposed between the inlet (14) and reservoir volume (24), and a window (18) through the casing (10) at the test volume (22), the permeable material (12) being capable of transporting an aqueous solution disposed within the casing (10) and defining a flow path extending from the sample inlet (14) through the test volume (22) and into communication with the reservoir volume (24), there being present a first protein having a binding site specific to a first epitope on the ligand, the first protein being immobilized at a test site (18′), and being disposed within the test volume (22) in fluid communication with the flow path and visible through the window (18), and there being sorbent material (12) in the reservoir volume (24) for drawing liquid sample along the flow path and into contact with the test site (18′). A method of the detection of a ligand in a liquid sample, which comprises: (A) transporting along a flow path in a test cell a solution, including a liquid sample suspected to contain a ligand and a conjugate, into contact with a test site visible through a window in a wall of the test cell, the test site having immobilized thereon a first protein having a binding site specific to a first epitope on the ligand, and the conjugate comprising colored particles coupled to a second protein selected from proteins having a binding site specific to a second epitope on the ligand and proteins which bind with the first protein in competition with the ligand; and (B) continuing transport of the solution to progressively produce at the test site a complex comprising the ligand for a time sufficient to visually determine through the window whether a color is developed at the test site.
Inventors
- 👤 David E. Charlton
- 👤 Neal W. Miller
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 08:36
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/76; B; B01; B01L; B01L3/00; B01L3/50; B01L3/502; B01L3/5023; G01N33/53; G01N33/543; G01N33/54313; G01N33/54366; G01N33/743; B01L2300/00; B01L2300/06; B01L2300/0681; B01L2300/08; B01L2300/0809; B01L2300/0825; B01L2400/00; B01L2400/04; B01L2400/0403; B01L2400/0406; Y; Y10; Y10S; Y10S435/00; Y10S435/805; Y10S435/81; Y10S435/97; Y10S436/00; Y10S436/807; Y10S436/81; Y10S436/811; Y10S436/814; Y10S436/815; Y10S436/817; Y10S436/818; Y10T; Y10T436/00; Y10T436/25; Y10T436/25375; Y10T436/255
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
153 words
A method of the detection of a ligand in a liquid sample, which comprises: (A) transporting along a flow path in a test cell a solution, including a liquid sample suspected to contain a ligand and a conjugate, into contact with a test site visible through a window in a wall of the test cell, the test site having immobilized thereon a first protein having a binding site specific to a first epitope on the ligand, and the conjugate comprising colored particles coupled to a second protein selected from proteins having a binding site specific to a second epitope on the ligand and proteins which bind with the first protein in competition with the ligand; and (B) continuing transport of the solution to progressively produce at the test site a complex comprising the ligand for a time sufficient to visually determine through the window whether a color is developed at the test site.
Claim 2
Independent Claim
153 words
A method of the detection of a ligand in a liquid sample, which comprises: (A) transporting along a flow path in a test cell a solution, including a liquid sample suspected to contain a ligand and a conjugate, into contact with a test site visible through a window in a wall of the test cell, the test site having immobilized thereon a first protein having a binding site specific to a first epitope on the ligand, and the conjugate comprising colored particles coupled to a second protein selected from proteins having a binding site specific to a second epitope on the ligand and proteins which bind with the first protein in competition with the ligand; and (B) continuing transport of the solution to progressively produce at the test site a complex comprising the ligand for a time sufficient to visually determine through the window whether a color is developed at the test site.
Claim 3
Dependent Claim
40 words
A method according to claim 1, wherein the test cell comprises a filtration means for filtering the liquid sample, and there is an additional step of transporting the sample through the filtration means before the sample contacts the test site.
Claim 4
Dependent Claim
35 words
A method according to claim 1 or 2, wherein the cross-sectional area of the flow path is restricted about the test site whereby ligand is localised at the test site during flow of solution thereby.
Claim 5
Independent Claim
47 words
A method according to any of claims 1 to 3, wherein there are additional steps of transporting the solution into contact with a control site visible through a window in a wall of the test cell and comparing the color of the test site and control site.
Claim 6
Dependent Claim
20 words
A method according to claim 4, wherein the control site comprises a negative control site free of the first protein.
Claim 7
Dependent Claim
24 words
A method according to claim 4, wherein the control site comprises a positive control site having immobilised thereon an authentic sample of the ligand.
Claim 8
Independent Claim
64 words
A method according to any of claims 1 to 6, wherein the second protein has a binding site specific to a second epitope on the ligand, and when the sample contains the ligand, the complex produced in step B comprises the ligand bound to both the first and second proteins, and color is produced by aggregation of said colored particles at the test site.
Claim 9
Independent Claim
82 words
A method according to any of claims 1 to 4, wherein the second protein binds with the first protein in competition with the ligand, and when the sample contains the ligand, the complex produced in step B comprises the ligand bound to the first protein, and when the sample is free of the ligand, the complex produced in step B comprises the conjugate bound to the first protein, and color is produced by aggregation of the colored particles at the test site.
Claim 10
Independent Claim
23 words
A method according to any of claims 1 to 8, wherein the conjugate is mixed with the liquid sample prior to step A.
Claim 11
Independent Claim
36 words
A method according to any of claims 1 to 8, wherein the conjugate is disposed in the flow path, the liquid being transported into solubilising contact with the conjugate prior to contact with the test site.
Claim 12
Independent Claim
29 words
A method according to any of claims 1 to 10, wherein the first and second proteins comprise antibodies and at least one of the proteins is a monoclonal antibody.
Claim 13
Independent Claim
26 words
A method according to any of claims 1 to 11, wherein the first protein has a binding site specific to an epitope of human chorionic gonadotropin.
Claim 14
Independent Claim
25 words
A method according to any of claims 1 to 11, wherein the first protein has a binding site specific to an epitope of human progesterone.
Claim 15
Dependent Claim
177 words
A test cell (5) for detecting a ligand in a liquid sample, which comprises an elongate casing (10) for housing a permeable material (12) and defining a liquid sample inlet (14), a reservoir volume (24), a test volume (22) interposed between the inlet (14) and reservoir volume (24), and a window (18) through the casing (10) at the test volume (22), the permeable material (12) being capable of transporting an aqueous solution disposed within the casing (10) and defining a flow path extending from the sample inlet (14) through the test volume (22) and into communication with the reservoir volume (24), there being present a first protein having a binding site specific to a first epitope on the ligand, the first protein being immobilized at a test site (18′), and being disposed within the test volume (22) in fluid communication with the flow path and visible through the window (18), and there being sorbent material (12) in the reservoir volume (24) for drawing liquid sample along the flow path and into contact with the test site (18′).
Claim 16
Dependent Claim
177 words
A test cell (5) for detecting a ligand in a liquid sample, which comprises an elongate casing (10) for housing a permeable material (12) and defining a liquid sample inlet (14), a reservoir volume (24), a test volume (22) interposed between the inlet (14) and reservoir volume (24), and a window (18) through the casing (10) at the test volume (22), the permeable material (12) being capable of transporting an aqueous solution disposed within the casing (10) and defining a flow path extending from the sample inlet (14) through the test volume (22) and into communication with the reservoir volume (24), there being present a first protein having a binding site specific to a first epitope on the ligand, the first protein being immobilized at a test site (18′), and being disposed within the test volume (22) in fluid communication with the flow path and visible through the window (18), and there being sorbent material (12) in the reservoir volume (24) for drawing liquid sample along the flow path and into contact with the test site (18′).
Claim 17
Dependent Claim
26 words
A cell according to claim 14, wherein there is a liquid sample filtering means disposed in the flow path between the inlet and the test site.
Claim 18
Dependent Claim
19 words
A cell according to claim 15, wherein the filtering means is defined by a portion of the permeable material.
Claim 19
Dependent Claim
37 words
A cell according to any of claims 14 to 16, wherein the cross-sectional area of the flow path is restricted about the test site so that ligand in liquid passing therealong is localised at the test site.
Claim 20
Dependent Claim
65 words
A cell according to any of claims 14 to 17, wherein there is a conjugate disposed in the flow path between the test site and the inlet, the conjugate comprising colored particles coupled to a second protein selected from proteins having a binding site specific to a second epitope on the ligand, and proteins which bind with the first protein in competition with the ligand.
Claim 21
Dependent Claim
20 words
A cell according to claim 18, wherein at least one of the first and second proteins is a monoclonal antibody.
Claim 22
Dependent Claim
41 words
A cell according to any of claims 14 to 19, wherein the casing defines a second window through the casing, and there is a control site in the cell in fluid communication with the flow path visible through the second window.
Claim 23
Dependent Claim
20 words
A cell according to claim 20, wherein the control site comprises a negative control site free of the first protein.
Claim 24
Dependent Claim
20 words
A cell according to claim 21, wherein the control site comprises latex particles disposed in contact with the permeable material.
Claim 25
Dependent Claim
24 words
A cell according to claim 20, wherein the control site comprises a positive control site having immobilised thereon an authentic sample of the ligand.
Claim 26
Dependent Claim
28 words
A cell according to any of claims 14 to 23, wherein the test site comprises an antibody fixed to latex particles disposed in contact with the permeable material.
Claim 27
Dependent Claim
22 words
A cell according to any of claims 14 to 24, wherein the first protein binds with an epitope of human chorionic gonadotropin.
Claim 28
Dependent Claim
21 words
A cell according to any of claims 14 to 24, wherein the first protein binds with an epitope of human progesterone.
References Cited (Backward Citations)
US4366241A
Cited
US4366241B1
Cited
EP0217403A2
Cited
EP0258963A2
Cited
DE8805565U1
Cited
EP0306336A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.